KR102725883B1 - 지방산 유도체 및 이의 용도 - Google Patents

지방산 유도체 및 이의 용도 Download PDF

Info

Publication number
KR102725883B1
KR102725883B1 KR1020207003568A KR20207003568A KR102725883B1 KR 102725883 B1 KR102725883 B1 KR 102725883B1 KR 1020207003568 A KR1020207003568 A KR 1020207003568A KR 20207003568 A KR20207003568 A KR 20207003568A KR 102725883 B1 KR102725883 B1 KR 102725883B1
Authority
KR
South Korea
Prior art keywords
compound
epoxy
delete delete
hydroxy
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003568A
Other languages
English (en)
Korean (ko)
Other versions
KR20200027545A (ko
Inventor
그레고리 키스
크리스토퍼 램즈던
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Publication of KR20200027545A publication Critical patent/KR20200027545A/ko
Application granted granted Critical
Publication of KR102725883B1 publication Critical patent/KR102725883B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C07C33/025—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond
    • C07C33/03—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond in beta-position, e.g. allyl alcohol, methallyl alcohol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207003568A 2017-07-07 2018-07-06 지방산 유도체 및 이의 용도 Active KR102725883B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529846P 2017-07-07 2017-07-07
US62/529,846 2017-07-07
PCT/US2018/041086 WO2019010414A1 (en) 2017-07-07 2018-07-06 FATTY ACID DERIVATIVES AND USE THEREOF

Publications (2)

Publication Number Publication Date
KR20200027545A KR20200027545A (ko) 2020-03-12
KR102725883B1 true KR102725883B1 (ko) 2024-11-01

Family

ID=63036390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003568A Active KR102725883B1 (ko) 2017-07-07 2018-07-06 지방산 유도체 및 이의 용도

Country Status (9)

Country Link
US (2) US11555021B2 (enExample)
EP (1) EP3649115B1 (enExample)
JP (1) JP7234151B2 (enExample)
KR (1) KR102725883B1 (enExample)
CN (1) CN110869354A (enExample)
AU (1) AU2018297192B2 (enExample)
CA (1) CA3064132C (enExample)
MX (1) MX391168B (enExample)
WO (1) WO2019010414A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
CN113121475B (zh) * 2021-03-30 2022-12-02 香港科技大学深圳研究院 不饱和脂肪酸类化合物及其制备方法和应用
CN113620923B (zh) * 2021-07-16 2023-03-14 扬州工业职业技术学院 一种低温电解液添加剂的制备方法及应用
CN115073295B (zh) * 2022-07-21 2023-12-26 山东大学 马齿苋中不饱和脂肪酸及其提取分离方法和应用
WO2024237316A1 (ja) * 2023-05-16 2024-11-21 国立大学法人東京大学 エポキシ化不飽和脂肪酸の皮膚線維化改善作用
EP4613730A1 (en) * 2024-03-05 2025-09-10 Centre National de la Recherche Scientifique Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022848A1 (en) * 1993-03-29 1994-10-13 Pace Asciak Cecil R Hepoxilin analogs useful as anti-inflammatory agents
WO1999000116A2 (en) * 1997-06-26 1999-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
WO2001005814A1 (en) * 1999-07-15 2001-01-25 Eli Lilly And Company Pseudomycin n-acyl side-chain analogs
JP2006513251A (ja) 2003-01-23 2006-04-20 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
WO2006106438A2 (en) 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
JP2012502035A (ja) 2008-09-04 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
JP2015518484A (ja) 2012-04-19 2015-07-02 ナイケン ホールディング ベーフェー ゲラニルゲラニルアセトン類似化合物及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055613A (en) * 1988-02-18 1991-10-08 G. D. Searle & Co. Metabolites of pentanedioic acid derivatives
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
DE102004037118A1 (de) 2004-07-30 2006-03-23 Degussa Ag Titandioxid enthaltende Dispersion
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
JP6160375B2 (ja) 2013-09-06 2017-07-12 ブラザー工業株式会社 画像記録装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022848A1 (en) * 1993-03-29 1994-10-13 Pace Asciak Cecil R Hepoxilin analogs useful as anti-inflammatory agents
WO1999000116A2 (en) * 1997-06-26 1999-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
WO2001005814A1 (en) * 1999-07-15 2001-01-25 Eli Lilly And Company Pseudomycin n-acyl side-chain analogs
JP2006513251A (ja) 2003-01-23 2006-04-20 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
WO2006106438A2 (en) 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
JP2012502035A (ja) 2008-09-04 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
JP2015518484A (ja) 2012-04-19 2015-07-02 ナイケン ホールディング ベーフェー ゲラニルゲラニルアセトン類似化合物及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Pharmacology Volume 785, 15 August 2016, Pages 70-76

Also Published As

Publication number Publication date
EP3649115B1 (en) 2024-09-04
EP3649115A1 (en) 2020-05-13
AU2018297192B2 (en) 2022-02-17
US20220274940A1 (en) 2022-09-01
JP7234151B2 (ja) 2023-03-07
AU2018297192A1 (en) 2019-12-19
US20210139440A1 (en) 2021-05-13
CN110869354A (zh) 2020-03-06
MX391168B (es) 2025-03-21
WO2019010414A1 (en) 2019-01-10
CA3064132C (en) 2024-06-04
US12479812B2 (en) 2025-11-25
JP2020526505A (ja) 2020-08-31
KR20200027545A (ko) 2020-03-12
CA3064132A1 (en) 2019-01-10
EP3649115C0 (en) 2024-09-04
US11555021B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US12479812B2 (en) Fatty acid derivatives and their use
Levy Resolvins and protectins: natural pharmacophores for resolution biology
Aursnes et al. Total synthesis of the lipid mediator PD1n-3 DPA: configurational assignments and anti-inflammatory and pro-resolving actions
Levy et al. Cysteinyl maresins regulate the prophlogistic lung actions of cysteinyl leukotrienes
EP2493296B1 (en) Alleviating oxidative stress disorders with pufa derivatives
US8338394B2 (en) Methods for treating metabolic diseases
KR20120046754A (ko) 히드록시 지방산 화합물 및 질병 치료 및 진단을 위한 그의 용도
JP6820312B2 (ja) アトルバスタチンにより増加し、炎症を消失させる新規な１３−シリーズのレゾルビンの解明
Balas et al. Rapid metabolization of protectin D1 by β-oxidation of its polar head chain
JP2021525803A (ja) カンナビノイド及びそれらの使用
Yang et al. Dietary fish oil enriched in very-long-chain polyunsaturated fatty acid reduces cardiometabolic risk factors and improves retinal function
KR20180066395A (ko) 유리 지방산을 포함하는 특발성 폐섬유증 예후예측용 바이오마커
US20050234025A1 (en) Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
Ervik et al. Synthesis of the methyl ester of 17 (R/S)-Me-RvD5n-3 DPA and relief of postoperative pain in male mice
Arai et al. Design and synthesis of cyclopropane congeners of resolvin E3, an endogenous pro-resolving lipid mediator, as its stable equivalents
RU2712229C2 (ru) Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора
Boots et al. Hypocholesterolemic agents I: 3‐methyl‐4‐phenylbutenoic acids
US20130072555A1 (en) Compositions and methods for treating metabolic diseases
EP3207926A1 (en) Oxidized lipids in the treatment of chronic or neuropathic pain
Mohd Fauzi et al. Lipid oxidation
WO2024073673A1 (en) Modulators of cd1 protein binding to t cell receptors
WO2005005433A1 (ja) 高カルシウム血症および骨疾患治療剤
Zhou Novel pathways in cholesterol metabolism to combat cardiometabolic diseases
WO2026039730A1 (en) Novel therapeutic compositions for treating addictions and methods of use thereof
Cozzi et al. Synthesis of 3-hydroxy-3-cyclohexylbutyric acid derivatives. 1. Cyclic homologs of 3-hydroxy-3-methylglutaric acid

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200206

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210706

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231205

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240826

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241030

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241030

End annual number: 3

Start annual number: 1

PG1601 Publication of registration